[1] Schulz M, Trebicka J. Acute-on-chronic liver failure: a global disease[J]. Gut, 2022,71(1):5-6.
[2] Hernaez R, Kramer J R, Liu Y, et al. Prevalence and short-term mortality of acute-on-chronic liver failure: a national cohort study from the USA[J]. J Hepatol, 2019,70(4):639-647.
[3] Arias C A, Murray B E. The rise of the enterococcus: beyond vancomycin resistance[J]. Nat Rev Microbiol, 2012,10(4):266-278.
[4] Mokhtar J A, Attallah D, Al-Rabia M W, et al. Epidemiology and clinical impact of vancomycin-resistant enterococcus at King Abdulaziz University Hospital (2015-2022): prevalence, risk factors, and mortality[J]. Int J Gen Med, 2025,18:2021-2031.
[5] Barger M, Blodget E, Pena S, et al. VRE in cirrhotic patients[J]. BMC Infect Dis, 2019,19(1):711.
[6] Miller W R, Murray B E, Rice L B, et al. Resistance in vancomycin-resistant enterococci[J]. Infect Dis Clin North Am, 2020,34(4):751-771.
[7] Caraceni P, Vargas V, Sola E, et al. The use of rifaximin in patients With cirrhosis[J]. Hepatology, 2021,74(3):1660-1673.
[8] Tranah T H, Edwards L A, Schnabl B, et al. Targeting the gut-liver-immune axis to treat cirrhosis[J]. Gut, 2021,70(5):982-994.
[9] Israelsen M, Madsen B S, Torp N, et al. Rifaximin-alpha for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2023,8(6):523-532.
[10] Patel V C, Lee S, McPhail M J W, et al. Rifaximin-alpha reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial[J]. J Hepatol, 2022,76(2):332-342.
[11] Turner A M, Li L, Monk I R, et al. Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin[J]. Nature, 2024,635(8040):969-977.
[12] Hong C, Chan L, Chen K, et al. Rifaximin modifies gut microbiota and attenuates inflammation in Parkinson′s disease: preclinical and clinical studies[J]. Cells, 2022,11(21).
[13] Giner-Perez L, Jarquin-Diaz V H, Leone P, et al. Rifaximin-induced changes in the gut microbiome associated to improvement of neurotransmission alterations and learning in rats with chronic liver disease[J]. Sci Rep, 2025,15(1):34382.
[14] Soldi S, Vasileiadis S, Uggeri F, et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach[J]. Clin Exp Gastroenterol, 2015,8:309-325.
[15] Ponziani F R, Zocco M A, D′Aversa F, et al. Eubiotic properties of rifaximin: disruption of the traditional concepts in gut microbiota modulation[J]. World J Gastroenterol, 2017,23(25):4491-4499.
[16] DuPont H L. The potential for development of clinically relevant microbial resistance to rifaximin-alpha: a narrative review[J]. Clin Microbiol Rev, 2023,36(4):e0003923.
[17] van Doorn D J, van Eekhout K M A, de Wit K, et al. Rifaximin-alpha in patients with rtecurrent episodes of hepatic encephalopathy due to cirrhosis reduces healthcare utilization[J]. United European Gastroenterol J, 2025,13(6):938-945.
[18] Jimenez C, Ventura-Cots M, Sala M, et al. Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: a pilot study (RIFA-AH)[J]. Liver Int, 2022,42(5):1109-1120.
[19] Rohde A M, Walker S, Behnke M, et al. Vancomycin-resistant enterococcus faecium: admission prevalence, sequence types and risk factors-a cross-sectional study in seven German university hospitals from 2014 to 2018[J]. Clin Microbiol Infect, 2023,29(4):515-522.
[20] Silvey S, Patel N, Khoruts A, et al. Rifaximin does not increase the rate of 30-day mortality in patients with cirrhosis and daptomycin in two national US-based cohorts[J]. Gastroenterology, 2025,169(2):349-351.
[21] Chambers H F, Arias C A. Rifaximin prophylaxis and collateral damage in patients with advanced liver disease[J]. Gastroenterology, 2025,169(2):212-213.
[22] Zeng X, Sheng X, Wang P, et al. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis[J]. Hepatol Int, 2021,15(1):155-165.
[23] Thevenot T, Elkrief L, Bureau C, et al. Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial[J]. J Hepatol, 2025.
[24] Bureau C, Thabut D, Jezequel C, et al. The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt : a randomized controlled trial[J]. Ann Intern Med, 2021,174(5):633-640.
[25] Kebriaei R, Stamper K C, Singh K V, et al. Mechanistic insights into the differential efficacy of daptomycin plus beta-lactam combinations against daptomycin-resistant enterococcus faecium[J]. J Infect Dis, 2020,222(9):1531-1539.
[26] Bajaj J S, Ng S C, Schnabl B. Promises of microbiome-based therapies[J]. J Hepatol, 2022,76(6):1379-1391.
[27] Shamsaddini A, Gillevet P M, Acharya C, et al. Impact of antibiotic resistance genes in gut microbiome of patients with cirrhosis[J]. Gastroenterology, 2021,161(2):508-521.
[28] Saboo K, Petrakov N V, Shamsaddini A, et al. Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning[J]. J Hepatol, 2022,76(3):600-607. |
